Is 25-hydroxycholesterol the interplay of statins and inflammation?

International Journal of Cardiology

Volumn 184, Issue 1, 2015, Pages 255-256

  Chen, Jiao Hua ^a   Peng, Dao Quan ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Cholesterol 25 hydroxylase; Inflammation; Oxysterol; Sepsis; Statins; Viral infection

Indexed keywords

25 HYDROXYCHOLESTEROL; CHOLESTEROL 25 HYDROXYLASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXYGENASE; ROSUVASTATIN; SIMVASTATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; UNCLASSIFIED DRUG; 25-HYDROXYCHOLESTEROL; CHOLESTEROL DERIVATIVE;

ANTIINFLAMMATORY ACTIVITY; ANTIVIRAL ACTIVITY; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR INFLAMMATION; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG MECHANISM; HUMAN; LETTER; NEGATIVE FEEDBACK; NONHUMAN; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PRENYLATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; SECONDARY PREVENTION; STEROL SYNTHESIS; VIRUS REPLICATION; DRUG COMBINATION; INFLAMMATION; METABOLISM;

DRUG THERAPY, COMBINATION; HUMANS; HYDROXYCHOLESTEROLS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INFLAMMATION;

EID: 84933516714     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.02.047     Document Type: Article

References (10)

1. S. Devaraj, D. Siegel, I. Jialal, Statin therapy in metabolic syndrome and hypertension post-Jupiter: what is the value of CRP? Curr. Atheroscler. Rep. 13 (2011) 31-42.
2. N. Tahara, H. Kai, M. Ishibashi, H. Nakaura, H. Kaida, K. Baba, et al., Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography, J. Am. Coll. Cardiol. 48 (2006) 1825-1831.
3. J.M. Patel, C. Snaith, D.R. Thickett, L. Linhartova, T. Melody, P. Hawkey, et al., Randomized double-blind placebo-controlled trial of 40 mg/day of atorvastatin in reducing the severity of sepsis in ward patients (ASEPSIS Trial), Crit. Care 16 (2012).
4. F.K.F. Cheng, D.M. Torres, S.A. Harrison, Hepatitis C and lipid metabolism, hepatic steatosis, and NAFLD: still important in the era of direct acting antiviral therapy? J. Viral Hepat. 21 (2014) 1-8.
5. M. Blanc, W.Y. Hsieh, K.A. Robertson, S. Watterson, G.H. Shui, P. Lacaze, et al., Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis, PLOS Biol. 9 (2011).
6. A. Simon, Cholesterol metabolism and immunity, N. Engl. J. Med. 371 (2014) 1933-1935.
7. A. Reboldi, E.V. Dang, J.G. McDonald, G. Liang, D.W. Russell, J.G. Cyster, Inflammation. 25-hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon, Science 345 (2014) 679-684.
8. J.G. Cyster, E.V. Dang, A. Reboldi, T. Yi, 25-Hydroxycholesterols in innate and adaptive immunity, Nat. Rev. Immunol. 14 (2014) 731-743.
9. S.Y. Liu, R. Aliyari, K. Chikere, G. Li, M.D. Marsden, J.K. Smith, et al., Interferoninducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol, Immunity 38 (2013) 92-105.
10. C. Casella, D.H. Miller, K. Lynch, A.S. Brodsky, Oxysterols synergize with statins by inhibiting SREBP-2 in ovarian cancer cells, Gynecol. Oncol. 135 (2014) 333-341.